At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 129 enrolled

Drug / intervention

Tamsulosin +1 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00151567

NCT00151567Phase 3Completed

Compare CT.gov

Interest of a Treatment With the alpha1-blocker Tamsulosin in the Elimination of Pelvis Ureteral Stones

Rennes University Hospital·interventional·Posted Sep 9, 2005·Updated Dec 4, 2012

In Brief

A Phase 3 clinical trial evaluating Tamsulosin and Placebo for Ureterolithiasis and Ureteral Calculi. Completed, enrolled 129 participants across 6 sites.

Detailed Summary

Ureteral stones have an important place in daily urological practice, usually causing acute episodes of ureteral colic by obstructing the urinary tract. The aim of the study is to evaluate whether repeated administration of tamsulosin, a drug routinely used in the treatment of lower urinary tract symptoms, could lower the delay of elimination of the stone in patients with pelvis ureterolithiasis.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsUreterolithiasis, Ureteral Calculi

CountriesFrance

CollaboratorsMinistry of Health, France, Yamanouchi

Timeline

Phase 3CompletedFinished

20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartFeb 2002

First PostedSep 2005

Primary CompletionDec 2006

TodayJul 2026

First PostedSep 9, 2005

Enrollment StartFeb 1, 2002

Primary CompletionDec 1, 2006

TodayJul 2, 2026

Enrollment to primary: 4.8 yearsPosted 20.8 years ago

Interventions

Tamsulosindrug

Oral tamsulosin once a day until stone elimination or the end of the follow-up (42 days)

Placebodrug

Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)